Vaccines

The Vaccines and Related Biological Products Advisory Committee approved the vaccine, BNT162b2, paving the way to emergency use authorization.

The report came out as the U.K. has started vaccinating patients.

As National Influenza Vaccination Week approaches, it’s time for all adults to get a flu shot.

The UK leapfrogged the rest of the western world in accepting the candidate which is shown to be about 95 percent effective against COVID-19.

The organization is recommending a framework to ensure ethical allocations of much-needed vaccines during the pandemic.

The candidate showed 94.1 percent efficacy against COVID-19 and 100 percent against severe COVID-19.

The company tested two different dosing regimens with one shown to be more effective.

The candidate BNT162b2 was shown to be 95 percent effective against COVID-19.

BNT162b2 showed 95 percent efficacy against COVID-19.

The latest vaccine candidate showed about 95 percent efficacy in a Phase 3 trial.

These new codes ensure physicians get paid for keeping their patients safe from COVID-19.

The candidate was shown to be more than 90 percent effective in preventing COVID-19 infection.

With infections on the rise at the start of flu season, the need for measures to limit transmission is as strong as ever.

The interim final rule with comment period would make the vaccine free to patients on Medicare and on most private health plans.

Concerns over efficacy and politics clouds hope for a vaccine to end the COVID-19 pandemic.

In an open letter, CEO Albert Bouria sought to give clarity to the drug’s development timeline.

The trial had been halted due to a side-effect in an English patient.

The pledge seeks to assuage fears that the Trump administration will rush a vaccine into production for political purposes.

In a letter, the agency pushes states to fast-track permitting and licensing for possible distribution sites.

The ACP says that staying up to date on vaccinations is more important than ever.

A trio of experts will discuss the prospects of a handful of COVID-19 vaccine candidates which are entering phase 3 trials.

The deal is for the companies to supply up to 600 million doses of a MRNA-based vaccine candidate.

The candidate is a joint effort of Oxford University and AstraZeneca.

In a 45-person phase one clinical trial the vaccine subjects who received the vaccine candidate showed high neutralizing antibody responses.

For people who love cats but are allergic to them, relief may be on the horizon-and cats, rather than humans, would be the ones to be vaccinated.